Second malignancies after treatment of diffuse large B-cell non-Hodgkin's lymphoma: A GISL cohort study

Stefano Sacchi, Luigi Marcheselli, Alessia Bari, Raffaella Marcheselli, Samantha Pozzi, Paolo G. Gobbi, Francesco Angrilli, Maura Brugiatelli, Pellegrino Musto, Massimo Federico

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

Background: Improved treatment has increased the life expectancy of patients with non-Hodgkin's lymphoma, but few studies have addressed the issue of second cancer in patients treated for diffuse large B-cell lymphoma. The aims of this study were to determine the incidence and time free of second cancers in this subset of patients. Design and Methods: We evaluated a cohort of 1280 patients with diffuse large B-cell lymphoma who were first treated between 1988 and 2003. We utilized the central database of the Gruppo Italiano Studio Linfomi, which includes data on demographics, clinical characteristics, laboratory parameters, treatment and follow-up of all patients with non-Hodgkin's lymphoma enrolled in clinical trials. Results: After a median follow-up of 51 months, 48 patients had developed a second cancer: 13 hematologic malignancies and 35 solid tumors. The overall standardized incidence ratio in our cohort (with a median age of 58 years) matched that of the general Italian population. The incidence ratio of second tumors was age related, and the age groups 20-39 and 40-59 years showed an increased risk. Overall, the cumulative incidence of second cancer was 8.2% at 15 years. A multivariate analysis showed that older age at the time of diagnosis of lymphoma had a negative influence on the time free of second tumors. Conclusions: In our cohort, only young patients showed an increased incidence ratio of second malignancies, while the incidence ratio in patients aged over 59 years matched the incidence in the Italian general population. Demographics, baseline characteristics, laboratory parameters and treatment modalities did not have any significant impact on the incidence ratio of a second cancer.

Original languageEnglish
Pages (from-to)1335-1342
Number of pages8
JournalHaematologica
Volume93
Issue number9
DOIs
Publication statusPublished - Sep 2008

Fingerprint

Second Primary Neoplasms
B-Cell Lymphoma
Non-Hodgkin's Lymphoma
Cohort Studies
Incidence
Lymphoma, Large B-Cell, Diffuse
Therapeutics
Demography
Neoplasms
Hematologic Neoplasms
Life Expectancy
Population
Lymphoma
Multivariate Analysis
Age Groups
Clinical Trials
Databases

Keywords

  • Diffuse large B-cell lymphoma
  • DLBCL
  • Non-Hodgkin's lymphoma
  • Risk factors
  • Second malignancies
  • Treatment

ASJC Scopus subject areas

  • Hematology

Cite this

Sacchi, S., Marcheselli, L., Bari, A., Marcheselli, R., Pozzi, S., Gobbi, P. G., ... Federico, M. (2008). Second malignancies after treatment of diffuse large B-cell non-Hodgkin's lymphoma: A GISL cohort study. Haematologica, 93(9), 1335-1342. https://doi.org/10.3324/haematol.12918

Second malignancies after treatment of diffuse large B-cell non-Hodgkin's lymphoma : A GISL cohort study. / Sacchi, Stefano; Marcheselli, Luigi; Bari, Alessia; Marcheselli, Raffaella; Pozzi, Samantha; Gobbi, Paolo G.; Angrilli, Francesco; Brugiatelli, Maura; Musto, Pellegrino; Federico, Massimo.

In: Haematologica, Vol. 93, No. 9, 09.2008, p. 1335-1342.

Research output: Contribution to journalArticle

Sacchi, S, Marcheselli, L, Bari, A, Marcheselli, R, Pozzi, S, Gobbi, PG, Angrilli, F, Brugiatelli, M, Musto, P & Federico, M 2008, 'Second malignancies after treatment of diffuse large B-cell non-Hodgkin's lymphoma: A GISL cohort study', Haematologica, vol. 93, no. 9, pp. 1335-1342. https://doi.org/10.3324/haematol.12918
Sacchi, Stefano ; Marcheselli, Luigi ; Bari, Alessia ; Marcheselli, Raffaella ; Pozzi, Samantha ; Gobbi, Paolo G. ; Angrilli, Francesco ; Brugiatelli, Maura ; Musto, Pellegrino ; Federico, Massimo. / Second malignancies after treatment of diffuse large B-cell non-Hodgkin's lymphoma : A GISL cohort study. In: Haematologica. 2008 ; Vol. 93, No. 9. pp. 1335-1342.
@article{445385513167423986b1cc635c5c22cf,
title = "Second malignancies after treatment of diffuse large B-cell non-Hodgkin's lymphoma: A GISL cohort study",
abstract = "Background: Improved treatment has increased the life expectancy of patients with non-Hodgkin's lymphoma, but few studies have addressed the issue of second cancer in patients treated for diffuse large B-cell lymphoma. The aims of this study were to determine the incidence and time free of second cancers in this subset of patients. Design and Methods: We evaluated a cohort of 1280 patients with diffuse large B-cell lymphoma who were first treated between 1988 and 2003. We utilized the central database of the Gruppo Italiano Studio Linfomi, which includes data on demographics, clinical characteristics, laboratory parameters, treatment and follow-up of all patients with non-Hodgkin's lymphoma enrolled in clinical trials. Results: After a median follow-up of 51 months, 48 patients had developed a second cancer: 13 hematologic malignancies and 35 solid tumors. The overall standardized incidence ratio in our cohort (with a median age of 58 years) matched that of the general Italian population. The incidence ratio of second tumors was age related, and the age groups 20-39 and 40-59 years showed an increased risk. Overall, the cumulative incidence of second cancer was 8.2{\%} at 15 years. A multivariate analysis showed that older age at the time of diagnosis of lymphoma had a negative influence on the time free of second tumors. Conclusions: In our cohort, only young patients showed an increased incidence ratio of second malignancies, while the incidence ratio in patients aged over 59 years matched the incidence in the Italian general population. Demographics, baseline characteristics, laboratory parameters and treatment modalities did not have any significant impact on the incidence ratio of a second cancer.",
keywords = "Diffuse large B-cell lymphoma, DLBCL, Non-Hodgkin's lymphoma, Risk factors, Second malignancies, Treatment",
author = "Stefano Sacchi and Luigi Marcheselli and Alessia Bari and Raffaella Marcheselli and Samantha Pozzi and Gobbi, {Paolo G.} and Francesco Angrilli and Maura Brugiatelli and Pellegrino Musto and Massimo Federico",
year = "2008",
month = "9",
doi = "10.3324/haematol.12918",
language = "English",
volume = "93",
pages = "1335--1342",
journal = "Haematologica",
issn = "0390-6078",
publisher = "NLM (Medline)",
number = "9",

}

TY - JOUR

T1 - Second malignancies after treatment of diffuse large B-cell non-Hodgkin's lymphoma

T2 - A GISL cohort study

AU - Sacchi, Stefano

AU - Marcheselli, Luigi

AU - Bari, Alessia

AU - Marcheselli, Raffaella

AU - Pozzi, Samantha

AU - Gobbi, Paolo G.

AU - Angrilli, Francesco

AU - Brugiatelli, Maura

AU - Musto, Pellegrino

AU - Federico, Massimo

PY - 2008/9

Y1 - 2008/9

N2 - Background: Improved treatment has increased the life expectancy of patients with non-Hodgkin's lymphoma, but few studies have addressed the issue of second cancer in patients treated for diffuse large B-cell lymphoma. The aims of this study were to determine the incidence and time free of second cancers in this subset of patients. Design and Methods: We evaluated a cohort of 1280 patients with diffuse large B-cell lymphoma who were first treated between 1988 and 2003. We utilized the central database of the Gruppo Italiano Studio Linfomi, which includes data on demographics, clinical characteristics, laboratory parameters, treatment and follow-up of all patients with non-Hodgkin's lymphoma enrolled in clinical trials. Results: After a median follow-up of 51 months, 48 patients had developed a second cancer: 13 hematologic malignancies and 35 solid tumors. The overall standardized incidence ratio in our cohort (with a median age of 58 years) matched that of the general Italian population. The incidence ratio of second tumors was age related, and the age groups 20-39 and 40-59 years showed an increased risk. Overall, the cumulative incidence of second cancer was 8.2% at 15 years. A multivariate analysis showed that older age at the time of diagnosis of lymphoma had a negative influence on the time free of second tumors. Conclusions: In our cohort, only young patients showed an increased incidence ratio of second malignancies, while the incidence ratio in patients aged over 59 years matched the incidence in the Italian general population. Demographics, baseline characteristics, laboratory parameters and treatment modalities did not have any significant impact on the incidence ratio of a second cancer.

AB - Background: Improved treatment has increased the life expectancy of patients with non-Hodgkin's lymphoma, but few studies have addressed the issue of second cancer in patients treated for diffuse large B-cell lymphoma. The aims of this study were to determine the incidence and time free of second cancers in this subset of patients. Design and Methods: We evaluated a cohort of 1280 patients with diffuse large B-cell lymphoma who were first treated between 1988 and 2003. We utilized the central database of the Gruppo Italiano Studio Linfomi, which includes data on demographics, clinical characteristics, laboratory parameters, treatment and follow-up of all patients with non-Hodgkin's lymphoma enrolled in clinical trials. Results: After a median follow-up of 51 months, 48 patients had developed a second cancer: 13 hematologic malignancies and 35 solid tumors. The overall standardized incidence ratio in our cohort (with a median age of 58 years) matched that of the general Italian population. The incidence ratio of second tumors was age related, and the age groups 20-39 and 40-59 years showed an increased risk. Overall, the cumulative incidence of second cancer was 8.2% at 15 years. A multivariate analysis showed that older age at the time of diagnosis of lymphoma had a negative influence on the time free of second tumors. Conclusions: In our cohort, only young patients showed an increased incidence ratio of second malignancies, while the incidence ratio in patients aged over 59 years matched the incidence in the Italian general population. Demographics, baseline characteristics, laboratory parameters and treatment modalities did not have any significant impact on the incidence ratio of a second cancer.

KW - Diffuse large B-cell lymphoma

KW - DLBCL

KW - Non-Hodgkin's lymphoma

KW - Risk factors

KW - Second malignancies

KW - Treatment

UR - http://www.scopus.com/inward/record.url?scp=50849120747&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=50849120747&partnerID=8YFLogxK

U2 - 10.3324/haematol.12918

DO - 10.3324/haematol.12918

M3 - Article

C2 - 18698083

AN - SCOPUS:50849120747

VL - 93

SP - 1335

EP - 1342

JO - Haematologica

JF - Haematologica

SN - 0390-6078

IS - 9

ER -